Clinical Trials | December 04, 2025
Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis
The company is excluding data from the affected sites to maintain the study's integrity
The company is excluding data from the affected sites to maintain the study's integrity
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Now a test that offers new precision in prostate cancer detection
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Subscribe To Our Newsletter & Stay Updated
